Article

The IDentif.AI 2.0 Pandemic Readiness Platform: Rapid Prioritization of Optimized COVID-19 Combination Therapy Regimens

2021-07-02

Abstract excerpt

<h4>Objectives</h4> We aimed to harness IDentif.AI 2.0, a clinically actionable AI platform to rapidly pinpoint and prioritize optimal combination therapy regimens against COVID-19. <h4>Methods</h4> A pool of starting candidate therapies was developed in collaboration with a community of infectious disease clinicians and included EIDD-1931 (metabolite of EIDD-2801), baricitinib, ebselen, selinexor, masitinib, nafa...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 76757e5d-2f5f-569b-97b0-f115d7f56230
DOI: 10.1101/2021.06.23.21259321

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The IDentif.AI 2.0 Pandemic Readiness Platform: Rapid Prioritization of Optimized COVID-19 Combination Therapy RegimensDOI 10.1101/2021.06.23.21259321Read

Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3)Semantic proximity Read

Identification of novel antiviral drug combinations in vitro and tracking their developmentSemantic proximity Read

An Overview on Drug Evolution and Trials on Pandemic COVID-19 InfectionSemantic proximity Read

Recognition of plausible therapeutic agents to combat COVID-19: An omics data based combined approachSemantic proximity Read

Bayesian model infers drug repurposing candidates for treatment of COVID-19Semantic proximity Read

Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19Semantic proximity Read

Global multi-omics and systems pharmacological strategy unravel the multi-targeted therapeutic potential of natural bioactive molecules against COVID-19: An in silico approachSemantic proximity Read

Network bioinformatics analysis provides insight into drug repurposing for COVID-19Semantic proximity Read

Developing New Drugs for the COVID-19 Emergency: Anatomy of the U.S. Response.Semantic proximity Read

The COVID-19 PHARMACOME: A method for the rational selection of drug repurposing candidates from multimodal knowledge harmonizationSemantic proximity Read

Optimizing Antiviral Therapy for COVID-19 With Learned Pathogenic ModelSemantic proximity Read

Identification of candidate repurposable drugs to combat COVID-19 using a signature-based approachSemantic proximity Read